These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31730595)

  • 1. Intraperitoneal Chemotherapy: The Lived Experiences of Taiwanese Patients With Ovarian Cancer.
    Chou JF; Lu Y
    Clin J Oncol Nurs; 2019 Dec; 23(6):E100-E106. PubMed ID: 31730595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palliative care opportunities for women with advanced ovarian cancer associated with intraperitoneal chemotherapy.
    Otis-Green S; Wakabayashi MT; Morgan R; Hakim A; Ferrell B; Sun V; Yang E; Grant M
    J Palliat Med; 2013 Jan; 16(1):44-53. PubMed ID: 23272673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
    Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
    Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
    Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.
    Burkett AM; Cohn DE; Copeland LJ
    Gynecol Oncol; 2007 Feb; 104(2):491-3. PubMed ID: 17150244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Kothari R; Nagel C; Koopmeiners JS; Ivy JJ; Geller M; Salani R; Argenta PA
    Gynecol Oncol; 2010 Dec; 119(3):491-5. PubMed ID: 20888625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 16. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
    Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
    Koo YJ; Lim KT
    Taiwan J Obstet Gynecol; 2015 Jun; 54(3):275-9. PubMed ID: 26166340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.